Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1997 1
1999 1
2001 1
2002 1
2003 1
2004 1
2005 1
2006 2
2009 1
2010 2
2011 1
2012 1
2013 1
2014 1
2015 2
2016 4
2017 3
2018 3
2019 3
2020 3
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.
Grommes C, Tang SS, Wolfe J, Kaley TJ, Daras M, Pentsova EI, Piotrowski AF, Stone J, Lin A, Nolan CP, Manne M, Codega P, Campos C, Viale A, Thomas AA, Berger MF, Hatzoglou V, Reiner AS, Panageas KS, DeAngelis LM, Mellinghoff IK. Grommes C, et al. Among authors: hatzoglou v. Blood. 2019 Jan 31;133(5):436-445. doi: 10.1182/blood-2018-09-875732. Epub 2018 Dec 19. Blood. 2019. PMID: 30567753 Free PMC article. Clinical Trial.
We conducted a phase 1b clinical trial to explore the sequential combination of ibrutinib (560 or 840 mg daily dosing) with high-dose methotrexate (HD-MTX) and rituximab in patients with CNS lymphoma (CNSL). HD-MTX was given at 3.5 g/m(2) every 2 weeks for a total of 8 dos …
We conducted a phase 1b clinical trial to explore the sequential combination of ibrutinib (560 or 840 mg daily dosing) with high-dose methot …
Standardized Reporting of Oncologic Response: Making Every Report Count.
Do RKG, Lefkowitz RA, Hatzoglou V, Ma W, Juluru K, Mayerhoefer M. Do RKG, et al. Among authors: hatzoglou v. Radiol Imaging Cancer. 2022 Jun;4(4):e220042. doi: 10.1148/rycan.220042. Radiol Imaging Cancer. 2022. PMID: 35657292 Free PMC article. No abstract available.
The eIF2A knockout mouse.
Golovko A, Kojukhov A, Guan BJ, Morpurgo B, Merrick WC, Mazumder B, Hatzoglou M, Komar AA. Golovko A, et al. Among authors: hatzoglou m. Cell Cycle. 2016 Nov 16;15(22):3115-3120. doi: 10.1080/15384101.2016.1237324. Epub 2016 Sep 29. Cell Cycle. 2016. PMID: 27686860 Free PMC article.
p27Kip1 regulates the microtubule bundling activity of PRC1.
Perchey RT, Serres MP, Nowosad A, Creff J, Callot C, Gay A, Manenti S, Margolis RL, Hatzoglou A, Besson A. Perchey RT, et al. Among authors: hatzoglou a. Biochim Biophys Acta Mol Cell Res. 2018 Nov;1865(11 Pt A):1630-1639. doi: 10.1016/j.bbamcr.2018.08.010. Epub 2018 Aug 16. Biochim Biophys Acta Mol Cell Res. 2018. PMID: 30327204 Free article.
We have identified PRC1 as a novel binding partner for p27(Kip1) (p27). p27 is a cyclin-CDK inhibitor that causes cell cycle arrest in G1. However, p27 has also been involved in the regulation of G2/M progression and cytokinesis, as well as of other cellular processes, inc …
We have identified PRC1 as a novel binding partner for p27(Kip1) (p27). p27 is a cyclin-CDK inhibitor that causes cell cycle arrest in G1. H …
Semisupervised Training of a Brain MRI Tumor Detection Model Using Mined Annotations.
Swinburne NC, Yadav V, Kim J, Choi YR, Gutman DC, Yang JT, Moss N, Stone J, Tisnado J, Hatzoglou V, Haque SS, Karimi S, Lyo J, Juluru K, Pichotta K, Gao J, Shah SP, Holodny AI, Young RJ; MSK MIND Consortium. Swinburne NC, et al. Among authors: hatzoglou v. Radiology. 2022 Apr;303(1):80-89. doi: 10.1148/radiol.210817. Epub 2022 Jan 18. Radiology. 2022. PMID: 35040676 Free PMC article.
Fast, light, and scalable: harnessing data-mined line annotations for automated tumor segmentation on brain MRI.
Swinburne NC, Yadav V, Murthy KNK, Elnajjar P, Shih HH, Panyam PK, Santilli A, Gutman DC, Pike L, Moss NS, Stone J, Hatzoglou V, Shah A, Juluru K, Shah SP, Holodny AI, Young RJ; M.S.K. MIND Consortium. Swinburne NC, et al. Among authors: hatzoglou v. Eur Radiol. 2023 Sep;33(9):6582-6591. doi: 10.1007/s00330-023-09583-3. Epub 2023 Apr 12. Eur Radiol. 2023. PMID: 37042979 Free PMC article.
Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted 89Zr-Pertuzumab PET/CT.
Ulaner GA, Carrasquillo JA, Riedl CC, Yeh R, Hatzoglou V, Ross DS, Jhaveri K, Chandarlapaty S, Hyman DM, Zeglis BM, Lyashchenko SK, Lewis JS. Ulaner GA, et al. Among authors: hatzoglou v. Radiology. 2020 Aug;296(2):370-378. doi: 10.1148/radiol.2020192828. Epub 2020 Jun 9. Radiology. 2020. PMID: 32515679 Free PMC article.
35 results